Mutations in the antifolate-resistance-associated genes dihydrofolate reductase and dihydropteroate synthase in Plasmodium vivax isolates from malaria-endemic countries.

Department of Parasitology, Kangwon National University College of Medicine, Chuncheon, Republic of Korea.
The American journal of tropical medicine and hygiene (Impact Factor: 2.53). 09/2010; 83(3):474-9. DOI: 10.4269/ajtmh.2010.10-0004
Source: PubMed

ABSTRACT Parasite dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) are known target enzymes of antifolate drugs used for the treatment and prophylaxis of persons with malaria. We sequenced the Plasmodium vivax dihydrofolate reductase (pvdhfr) and dihydropteroate synthase (pvdhps) genes to examine the prevalence and extent of point mutations in isolates from malaria-endemic countries. Double mutations (S58R and S117N) or quadruple mutations (F57L/I, S58R, T61M, and S117T) in the pvdhfr gene were found in isolates from Thailand (96.4%) and Myanmar (71.4%), but in only one isolate (1.0%) from Korea, where sulfadoxine-pyrimethamine has never been used. The pvdhfr point mutations correlated strongly with the pvdhps point mutations and ranged from single to triple mutations (S382A, A383G, and A553G), among isolates from Thailand, Myanmar, and Korea. These findings suggests that the prevalence of mutations in pvdhfr and pvdhps in P. vivax isolates from different malaria-endemic countries is associated with selection pressure imposed by sulfadoxine-pyrimethamine.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasmodium vivax is the predominant species of human malaria parasites present in China. Although sulphadoxine-pyrimethamine (SP) and chloroquine (CQ) have been widely used for malaria treatment in China, the resistance profiles of these drugs are not available. Analysis of dihydrofolate reductase (dhfr), dihydropteroate synthase (dhps), and multidrug resistance (mdr-1) gene mutations in P. vivax isolates is a valuable molecular approach for mapping resistance to SP and CQ. This study investigates the prevalence of pvdhfr, pvdhps, and pvmdr-1 of P. vivax clinical isolates from China and provides baseline molecular epidemiologic data on SP- and CQ-associated resistance in P. vivax.
    Malaria Journal 09/2014; 13(1):346. · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sulphadoxine-Pyrimethamine has never been recommended for the treatment of P vivax malaria as the parasite is intrinsically resistant to pyrimethamine. The combination was introduced as a promising agent to treat P. falciparum malaria in many countries, but was withdrawn after a few years due to development and spread of resistant strains. Presently Sulphadoxine-Pyrimethamine is used as a partner drug of artemisinin-based combination therapy to treat uncomplicated falciparum malaria, a combination of Artesunate+Sulphadoxine-Pyrimethamine that is currently in use in India. In countries like India where both P. vivax and P. falciparum are equally prevalent, some proportion of P. vivax is exposed to Sulphadoxine-Pyrimethamine due to misdiagnosis and mixed infection. As reports on in-vivo therapeutic efficacy of Sulphadoxine-Pyrimethamine in P. vivax is rare, so the study on mutations in marker genes pvdhfr and pvdhps is important for pressure prediction and Sulphadoxine-Pyrimethamine resistance monitoring.We studied the prevalence of point mutations and haplotypes of both the genes in 80 P. vivax isolates collected from urban Kolkata by DNA sequencing method.Point mutation rates in both the genes were low. Double mutant pvdhfr A15N50R58N117I173 and single mutant pvdhps genotype S382G383K512A553V585 were more prevalent, while 35% isolates harboured wild genotype. Triple mutant ANRNI-SGKAV was found in 29.9% isolates. No quintuple mutant genotype was recorded.The P. vivax parasites in urban Kolkata may still be susceptible to Sulphadoxine-Pyrimethamine. Hence combination of anti-malarial drug combination like Artesunate+Sulphadoxine-Pyrimethamine introduced for P. falciparum might be effective in P. vivax also. Therapeutic efficacy study of this combination in P. vivax is thus strongly suggested.
    Antimicrobial Agents and Chemotherapy 10/2013; · 4.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The emergence and spread of multidrug resistant (MDR) malaria caused by Plasmodium falciparum or Plasmodium vivax have become increasingly important in the Greater Mekong Subregion (GMS). MDR malaria is the heritable and hypermutable property of human malarial parasite populations that can decrease in vitro and in vivo susceptibility to proven antimalarial drugs as they exhibit dose-dependent drug resistance and delayed parasite clearance time in treated patients. MDR malaria risk situations reflect consequences of the national policy and strategy as this influences the ongoing national-level or subnational-level implementation of malaria control strategies in endemic GMS countries. Based on our experience along with current literature review, the design of ecotope-based entomological surveillance (EES) and molecular xenomonitoring of MDR falciparum and vivax malaria parasites in Anopheles vectors is proposed to monitor infection pockets in transmission control areas of forest and forest fringe-related malaria, so as to bridge malaria landscape ecology (ecotope and ecotone) and epidemiology. Malaria ecotope and ecotone are confined to a malaria transmission area geographically associated with the infestation of Anopheles vectors and particular environments to which human activities are related. This enables the EES to encompass mosquito collection and identification, salivary gland DNA extraction, Plasmodium- and species-specific identification, molecular marker-based PCR detection methods for putative drug resistance genes, and data management. The EES establishes strong evidence of Anopheles vectors carrying MDR P. vivax in infection pockets epidemiologically linked with other data obtained during which a course of follow-up treatment of the notified P. vivax patients receiving the first-line treatment was conducted. For regional and global perspectives, the EES would augment the epidemiological surveillance and monitoring of MDR falciparum and vivax malaria parasites in hotspots or suspected areas established in most endemic GMS countries implementing the National Malaria Control Programs, in addition to what is guided by the World Health Organization.
    Interdisciplinary Perspectives on Infectious Diseases 01/2014; 2014:969531.

Full-text (2 Sources)

Available from
May 27, 2014